Literature DB >> 21958195

Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana.

M Demar1, D Hommel, F Djossou, C Peneau, R Boukhari, D Louvel, A-M Bourbigot, V Nasser, D Ajzenberg, M-L Darde, B Carme.   

Abstract

Atypical Toxoplasma gondii strains, unrelated to archetypal clonal lineages (I, II, III), have been reported more frequently over the last decade in areas other than Europe and North America. A newly described form of toxoplasmosis, 'Amazonian toxoplasmosis' (AT), has been reported since 2002 in French Guiana. It is characterized by severe cases and atypical strains linked to a neotropical forest-based cycle. We report on the cases of AT that required intensive care management. We performed a prospective observational study on hospitalized adults in the Intensive Care Unit (ICU) from 2002 to 2008. Clinical and laboratory data, microbiological findings and outcomes were recorded. Data, including the ICU simplified acute physiology score and the pneumonia severity index, were calculated. Epidemiological risk factors for AT were assessed through questionnaires. Eleven non-immunodeficient patients were admitted to the ICU in Cayenne for life-threatening pneumonia associated with disseminated toxoplasmosis. Mechanical ventilation was necessary in seven patients, four of whom required immediate orotracheal intubation. Cardiac and ophthalmological abnormalities were found in five and four patients, respectively. One patient died from multiple organ failure. The genetic characterization of Toxoplasma DNA using six microsatellite markers revealed unique and atypical genotypes in eight patients. All patients presented epidemiological risk factors for AT. In French Guiana, significant T. gondii-related infectious syndrome associated with the lungs, a high level of LDH activity and the reported risk factors for AT was strongly suggestive of disseminated toxoplasmosis with a possible trend toward life-threatening pneumonia.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958195     DOI: 10.1111/j.1469-0691.2011.03648.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  38 in total

1.  Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.

Authors:  J Stone Doggett; Kayode K Ojo; Erkang Fan; Dustin J Maly; Wesley C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 2.  Toxoplasma Effectors Targeting Host Signaling and Transcription.

Authors:  Mohamed-Ali Hakimi; Philipp Olias; L David Sibley
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  Toxoplasma genotyping in congenital toxoplasmosis in Upper Egypt: evidence of type I strain.

Authors:  Hanan E M Eldeek; Alzahraa Abdel Raouf Ahmad; Mohamed Ahmed El-Mokhtar; Abdel Rahman M M Abdel Kader; Ahmad M Mandour; Mahmoud Elhady M Mounib
Journal:  Parasitol Res       Date:  2017-07-01       Impact factor: 2.289

4.  Molecular and virulence characterization of Toxoplasma gondii strains isolated from humans in Portugal.

Authors:  Anabela Vilares; Maria João Gargaté; Idalina Ferreira; Susana Martins; João Paulo Gomes
Journal:  Parasitol Res       Date:  2017-01-30       Impact factor: 2.289

5.  Recurrent seizures during acute acquired toxoplasmosis in an immunocompetent traveller returning from Africa.

Authors:  Anna Beltrame; Sergio Venturini; Giovanni Crichiutti; Valeria Meroni; Dora Buonfrate; Matteo Bassetti
Journal:  Infection       Date:  2015-07-14       Impact factor: 3.553

6.  Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.

Authors:  Steven M Johnson; Ryan C Murphy; Jennifer A Geiger; Amy E DeRocher; Zhongsheng Zhang; Kayode K Ojo; Eric T Larson; B Gayani K Perera; Edward J Dale; Panqing He; Molly C Reid; Anna M W Fox; Natascha R Mueller; Ethan A Merritt; Erkang Fan; Marilyn Parsons; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2012-02-27       Impact factor: 7.446

7.  Prevalence of Toxoplasma gondii infection in HIV-infected patients and food animals and direct genotyping of T. gondii isolates, Southern Ghana.

Authors:  Faustina Pappoe; Weisheng Cheng; Lin Wang; Yuanling Li; Dorcas Obiri-Yeboah; Samuel Victor Nuvor; Henock Ambachew; Xiaodong Hu; Qingli Luo; Deyong Chu; Yuanhong Xu; Jilong Shen
Journal:  Parasitol Res       Date:  2017-04-22       Impact factor: 2.289

Review 8.  Molecules to modeling: Toxoplasma gondii oocysts at the human-animal-environment interface.

Authors:  Elizabeth VanWormer; Heather Fritz; Karen Shapiro; Jonna A K Mazet; Patricia A Conrad
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2012-12-04       Impact factor: 2.268

9.  Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Authors:  Joshua B Radke; Jeremy N Burrows; Daniel E Goldberg; L David Sibley
Journal:  ACS Infect Dis       Date:  2018-07-25       Impact factor: 5.084

Review 10.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.